Perfectly Aligned With the Global Shift Toward Non-Invasive Care
Consumers are moving decisively toward treatments that are:
- non-invasive
- natural
- regenerative
- downtime-free
ARIAN™ technology sits at the centre of these mega-trends.
FOR INVESTORS
Why Invest in ARIAN™ Technology
Two fast‑growing, highly scalable revenue streams:
Clinical and Research
ARIAN™ Technology:
A Breakthrough Platform
Our platform is positioned at the heart of the fast‑growing personalised skin‑treatment segment in regenerative medicine.
ARIAN™ brings a new level of flexibility by allowing patients to take their treatment home. For clinics, it opens an additional revenue stream, as the treatment can be provided by non‑physician staff at a lower hourly rate while still maintaining high standards of care. This also frees the doctor to perform other higher‑value treatments at the same time, increasing overall clinic productivity and generating recurring revenue.
A Disruptive, Needle-Free Alternative to PRP
While the global PRP market continues to expand at double-digit growth, it remains limited by one major barrier: injections. ARIAN™ technology removes that barrier entirely. This is not an incremental improvement but a step-change innovation that unlocks a significantly larger addressable market.
Additional Revenue Beyond Clinical Use
Two components of the ARIAN™ platform have already gained international scientific interest:
- DSD (Digital Platelet Storage Device)
- CRP-A (Collagen-Related Peptide A)
These technologies are already in use across four continents by leading universities, research laboratories, R&D centres, and major companies already generating revenue channels and validating the scientific strength of the platform.
DSD
CRP-A
Future Markets
A Much Larger Opportunity Ahead
While the skin market is the first commercial application for ARIAN™ technology, the future expansion into wound care represents an even larger opportunity.
The global wound-care market is already enormous, valued between $22.28B and $24.9B today, depending on the report. It is projected to grow to $33.6B–$44.2B over the next decade, with a steady CAGR of 4.2%–5.9%.
As ARIAN™ technology advances into wound-care applications, it positions Pplus to participate in one of the largest and most stable sectors in global healthcare, unlocking a long-term, multi-billion-dollar growth pathway far beyond skin market.
global wound-care market VALUE
$22.28B+
PROJECTED GROWTH NEXT DECADE
$33.6B+
with a steady CAGR of 4.2%–5.9%.
Send us a message
For access to our detailed investor materials, including historical financials, forecasts and projections, funding history, cap table, key commercial metrics, market and regulatory information, and the presentation deck, we invite interested investors to contact our CEO directly. We provide this information privately to ensure transparency while maintaining appropriate confidentiality.
For more information, please contact our CEO, Dr. Mitra Najafi, at
mitra@pplusmedical.com